List of Excipients in Branded Drug TOFIDENCE

Tofidence Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Tofidence (tocilizumab-bavi) is Biogen’s intravenous tocilizumab biosimilar, developed with Bio-Thera Pharmaceuticals and approved by the FDA in September 2023. Its commercial opportunity is based on lower-cost substitution for Actemra, hospital procurement, and expansion of biologic access in rheumatoid arthritis and juvenile idiopathic arthritis. The current excipient system is conservative and clinically validated: sucrose, sodium chloride, phosphate buffers, polysorbate 80, and water for injection. The largest formulation opportunities are not simple excipient substitutions. They are vial optimization, ready-to-use presentations, supply-chain differentiation, and potentially subcutaneous or higher-concentration delivery systems that would require separate regulatory development. [1][2]

What is Tofidence and how is it regulated?

Tofidence is a biosimilar to Genentech’s Actemra, whose active ingredient is tocilizumab, a recombinant humanized monoclonal antibody against the interleukin-6 receptor.

Attribute	Tofidence
Active ingredient	Tocilizumab-bavi
Reference product	Actemra, tocilizumab
Sponsor	Biogen Inc.
Development partner	Bio-Thera Pharmaceuticals
FDA pathway	351(k) biosimilar application
FDA approval	September 29, 2023
Dosage form	Intravenous infusion concentrate
Strength	20 mg/mL
Presentations	80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL single-dose vials
Approved U.S. indications	Adult rheumatoid arthritis; pediatric polyarticular juvenile idiopathic arthritis; pediatric systemic juvenile idiopathic arthritis
Administration	Intravenous infusion after dilution
Preservative status	Preservative-free, single-dose vials

Tofidence is not an interchangeable biosimilar under the original FDA approval. The FDA approved it as a biosimilar, but the prescribing information does not identify it as interchangeable with Actemra. Automatic pharmacy substitution therefore does not apply in the same manner as it does for an interchangeable biosimilar. [1]

Tofidence is regulated under the Public Health Service Act. It is listed in the FDA Purple Book rather than the Orange Book. The Orange Book is principally used for small-molecule drugs approved under the Federal Food, Drug, and Cosmetic Act. [3]

What excipients are used in Tofidence?

The Tofidence formulation uses a conventional liquid monoclonal-antibody excipient platform.

Excipient or vehicle	Primary formulation function
Sucrose	Protects the antibody during manufacturing, storage, and freezing or thawing stress
Sodium chloride	Controls tonicity and ionic strength
Sodium phosphate dibasic dodecahydrate	Buffer component
Sodium phosphate monobasic dihydrate	Buffer component
Polysorbate 80	Limits interfacial stress and aggregation
Water for injection	Sterile liquid vehicle

Tofidence is supplied at 20 mg/mL in single-dose vials. The vial solution is diluted in 0.9% sodium chloride before intravenous administration. The product is not formulated with a preservative, which is consistent with single-dose parenteral use and reduces concerns about preservative toxicity, immunogenicity, and compatibility. [2]

The excipient system has four commercial advantages:

1. It uses familiar parenteral excipients with extensive regulatory precedent.
2. It supports a liquid product that avoids reconstitution.
3. It permits multiple vial sizes at one concentration.
4. It minimizes formulation changes that could complicate biosimilarity, immunogenicity, or comparability assessments.

How does Tofidence compare with Actemra excipients?

Tofidence and Actemra use broadly similar excipient concepts, but excipient identity alone does not establish formulation equivalence. The regulatory comparison concerns the total product, including higher-order structure, aggregates, charge variants, glycosylation, potency, impurities, stability, and clinical immunogenicity.

Commercial factor	Tofidence	Actemra
Product class	Tocilizumab biosimilar	Reference biologic
IV concentration	20 mg/mL	20 mg/mL
IV vial strategy	80 mg, 200 mg, 400 mg	Comparable weight-based dosing presentations
Core stabilizer	Sucrose	Sucrose-based formulation platform
Surfactant	Polysorbate 80	Polysorbate-containing formulation
Administration	IV infusion	IV infusion
Subcutaneous option	Not established in the current Tofidence label	Actemra has subcutaneous presentations
Interchangeability	Not designated interchangeable	Reference product

The closest competitive weakness is route breadth. Actemra has an established subcutaneous franchise, while Tofidence is positioned as an intravenous product. A biosimilar sponsor seeking subcutaneous Tofidence would need to demonstrate formulation, device, pharmacokinetic, immunogenicity, and usability comparability through an appropriate FDA submission.

What excipient strategy supports Tofidence commercial growth?

The current strategy prioritizes regulatory certainty and manufacturing robustness rather than formulation novelty.

Polysorbate 80 control

Polysorbate 80 protects the antibody against agitation and air-liquid interface stress. Its degradation can generate free fatty acids, subvisible particles, and oxidation-related impurities. For Tofidence, commercial quality programs should monitor:

• Peroxide and aldehyde content
• Fatty-acid degradation products
• Subvisible and visible particles
• Protein aggregation
• Monoclonal-antibody oxidation
• Container-closure compatibility

Polysorbate 80 is also a potential source of lot-to-lot variability. Supplier qualification, controlled storage, and incoming-material testing can protect consistency without changing the approved formulation.

Sucrose as the stabilizer

Sucrose provides stabilization without introducing the reducing-sugar chemistry associated with some alternative sugars. It supports a liquid formulation and has broad use in antibody products. A switch to trehalose or another stabilizer could create development opportunities, but it would also require new stability, comparability, process, and potentially clinical justification.

Phosphate-buffer management

Phosphate buffers are familiar and inexpensive, but phosphate concentration can influence protein solubility, aggregation, and pH drift during storage. Buffer optimization can be valuable in future presentations, particularly if the product moves toward higher concentration, extended in-use stability, or subcutaneous administration.

Preservative-free packaging

The preservative-free, single-dose vial format is appropriate for hospital infusion. It reduces formulation complexity and avoids benzyl alcohol, phenol, or m-cresol exposure. The tradeoff is that each vial is single-use, increasing residual drug and waste risk when patient doses do not align with vial sizes.

What formulation patents protect Tofidence and Actemra?

Tofidence does not have the same patent profile as a conventional small-molecule generic. The principal regulatory protection is the reference product’s biologic exclusivity and any applicable patent rights, while Tofidence entered through the 351(k) biosimilar pathway.

Legal issue	Tofidence position
Orange Book listing	Not the primary listing system for this biologic
Purple Book listing	Applicable
ANDA Paragraph IV challenge	Not applicable
BPCIA patent process	Applicable to biosimilar patent disputes
Reference-product exclusivity	Actemra’s 12-year U.S. biologic exclusivity period has expired
Product-specific formulation freedom	Limited by biosimilarity and manufacturing comparability requirements
Interchangeability	Not granted in the original approval

A Paragraph IV certification is an ANDA mechanism for small-molecule drugs. Tofidence did not enter through an ANDA, so a conventional Paragraph IV generic challenge is not the relevant framework. Patent disputes can still arise under the Biologics Price Competition and Innovation Act, including patent-list exchanges and infringement actions.

Actemra was FDA-approved in 2010. Its statutory 12-year reference-product exclusivity period therefore expired before Tofidence approval. The remaining barriers were patent rights, regulatory development, manufacturing readiness, and commercial contracting rather than unexpired reference-product exclusivity. [1][3][4]

When does Tofidence lose exclusivity?

Tofidence does not have a single generic-drug exclusivity date equivalent to an Orange Book small-molecule product.

The practical exclusivity timeline is:

Event	Timing
Actemra U.S. approval	2010
Actemra 12-year biologic exclusivity	Expired in 2022
Tofidence FDA approval	September 2023
Tofidence market entry	Subject to patent and settlement conditions
Competing tocilizumab biosimilars	Dependent on FDA approval, patent clearance, and contracting

Because Tofidence is itself a biosimilar, its commercial protection depends on manufacturing scale, contracting, supply reliability, customer service, and any patents covering its own processes or presentations. FDA approval does not prevent other sponsors from developing competing tocilizumab biosimilars.

What commercial opportunities exist for Tofidence excipients and packaging?

Hospital vial optimization

The current 80 mg, 200 mg, and 400 mg vial sizes support weight-based dosing but do not eliminate residual drug. A manufacturer could model hospital waste by patient weight, dosing interval, and vial combination. The highest-value opportunity is not necessarily a new excipient. It is a presentation that reduces discarded drug while preserving the 20 mg/mL formulation.

Potential approaches include:

• Additional vial sizes
• More efficient vial combinations
• Contract-specific packaging configurations
• Improved dose-rounding protocols
• Centralized pharmacy preparation support

Any new vial size would require regulatory approval and manufacturing validation.

Ready-to-use infusion products

A ready-to-use diluted bag or pharmacy-compounded alternative could reduce preparation time and handling risk. Commercial value would come from workflow efficiency, not merely lower drug acquisition cost. The development burden includes container compatibility, particulate control, in-use stability, shipping qualification, and administration instructions.

Extended in-use stability

Hospitals value flexibility when infusion schedules change. A formulation or packaging system that supports longer refrigerated or room-temperature in-use periods could reduce pharmacy waste. This opportunity depends on validated stability after dilution, container contact, light exposure, agitation, and microbial-control conditions.

Higher-concentration or subcutaneous delivery

Higher concentration can reduce injection volume and support subcutaneous administration. However, subcutaneous development introduces viscosity, injection-force, pain, aggregation, and device compatibility issues. A higher-concentration formulation could require changes to sucrose, buffer, surfactant, protein concentration, and container closure.

The commercial upside would be material because subcutaneous administration can shift treatment from infusion centers to outpatient or home settings. The regulatory route would likely require a supplemental or new biologics application, depending on the product and clinical package.

What manufacturing and excipient barriers affect Tofidence?

The most important manufacturing barriers are control of protein aggregation, polysorbate degradation, viral safety, aseptic filling, and cold-chain distribution.

Drug-substance manufacturing

Tocilizumab is a complex monoclonal antibody. Commercial success requires consistent control of:

• Cell-culture productivity
• Glycosylation
• Charge heterogeneity
• Host-cell proteins
• Host-cell DNA
• Aggregates and fragments
• Viral clearance
• Potency and receptor binding

Excipient changes can alter the stability profile and may expose differences that are not obvious from the label. For biosimilars, a novel excipient system can increase analytical and regulatory risk.

Fill-finish and container closure

Single-dose vials require validated protection against:

• Extractables and leachables
• Silicone-oil interaction
• Stopper incompatibility
• Particulates
• Container breakage
• Freeze-thaw stress
• Shipping vibration

A ready-to-use bag, prefilled syringe, or autoinjector would create separate compatibility and device-control requirements.

Which companies challenge Actemra and Tofidence commercially?

The competitive field includes the reference product, Tofidence, and other tocilizumab biosimilar developers. The principal commercial dimensions are price, hospital formulary access, infusion-center service, supply reliability, route of administration, and payer coverage.

Competitor category	Commercial position
Actemra	Broadest originator experience and established IV and subcutaneous use
Tofidence	FDA-approved U.S. tocilizumab biosimilar with hospital and payer discount potential
Other biosimilars	Future price pressure and contracting competition
Alternative IL-6 therapies	Compete for rheumatoid arthritis and inflammatory-disease treatment budgets

The main near-term market is institutional purchasing. Tofidence can compete where hospitals prioritize acquisition cost and where IV administration is already embedded in treatment pathways. Its lack of interchangeability designation limits automatic substitution but does not prevent physician-directed use or formulary placement.

What revenue exposure does Tofidence create for Biogen?

Tofidence gives Biogen exposure to the U.S. tocilizumab market without requiring originator ownership of the reference product. Revenue depends on:

• Net price after rebates
• Conversion from Actemra
• Hospital and group-purchasing contracts
• Availability of both 80 mg and larger vial sizes
• Supply continuity
• Expansion in pediatric indications
• Future interchangeability or additional presentations

The product also creates a defense against competitors entering the same market with lower prices. That defense depends on manufacturing scale and contracting execution. A biosimilar can gain volume while producing lower revenue per unit, so market share and margin must be evaluated separately.

How strong is the Tofidence excipient strategy?

The excipient strategy is strong for initial commercialization because it is conservative, familiar, and aligned with intravenous monoclonal-antibody manufacturing. It is weaker as a long-term differentiation platform because competitors can use similar excipients and match the same 20 mg/mL presentation.

Dimension	Assessment
Regulatory familiarity	Strong
Manufacturing simplicity	Strong
Cost efficiency	Strong
Differentiation	Limited
Hospital usability	Moderate
Subcutaneous potential	Requires new development
Waste reduction	Dependent on vial architecture
Biosimilarity risk	Lower than with a novel excipient system

The highest-return strategy is likely to preserve the approved excipient system while improving packaging, vial economics, in-use stability, and route options. A wholesale excipient redesign would have a higher technical and regulatory burden with limited immediate commercial benefit.

Key Takeaways

• Tofidence is an FDA-approved intravenous tocilizumab biosimilar marketed by Biogen and developed with Bio-Thera.
• Its formulation uses sucrose, polysorbate 80, phosphate buffers, sodium chloride, and water for injection.
• The excipient platform is conventional, preservative-free, and appropriate for single-dose hospital infusion.
• The product is listed through the Purple Book framework, not the conventional Orange Book system.
• Paragraph IV litigation does not apply because Tofidence was approved under the 351(k) biosimilar pathway.
• The largest commercial opportunities are vial optimization, hospital contracting, ready-to-use presentations, improved in-use stability, and possible subcutaneous development.
• Excipient changes should be approached cautiously because they may affect biosimilarity, aggregation, immunogenicity, and comparability.
• Actemra’s 12-year biologic exclusivity expired before Tofidence approval, leaving patents, manufacturing, and commercial execution as the main competitive barriers.

FAQs

Can Tofidence use the same excipients as Actemra?

Yes. Tofidence uses a comparable excipient strategy, but regulatory biosimilarity depends on the complete product profile rather than excipient identity alone.

Is Tofidence interchangeable with Actemra?

The original FDA approval did not designate Tofidence as interchangeable with Actemra. Physician-directed substitution remains possible, but automatic pharmacy substitution rules for interchangeable biosimilars do not apply.

Does Tofidence have an Orange Book patent?

Tofidence is a biologic and is not analyzed through the Orange Book in the same way as an ANDA-approved small-molecule drug. The FDA Purple Book and BPCIA framework are more relevant.

Can Tofidence be reformulated for subcutaneous injection?

A subcutaneous version is technically possible, but it would require development of a suitable concentration, viscosity, device, container, stability profile, and regulatory submission.

What is the most valuable excipient opportunity for Tofidence?

The strongest opportunity is likely improved operational performance, such as longer diluted-product stability or a ready-to-use presentation, rather than replacing the current sucrose-polysorbate-phosphate system.

References

1. U.S. Food and Drug Administration. (2023). TOFIDENCE (tocilizumab-bavi) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). TOFIDENCE approval package and product labeling. FDA.

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.

4. U.S. Food and Drug Administration. (2020). Biosimilar and interchangeable biosimilar biological products: Questions and answers. FDA.